Cover Image

Considerations for Single-Arm Trials to Support Accelerated Approval of Oncology Drugs

Fuente: arXiv

Saved in:

Bibliographic Details
Main Authors:	Lu, Feinan, Wang, Tao, Lu, Ying, Chen, Jie
Format:	Preprint
Published:	2024
Subjects:	Applications
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Digital Twins as Synthetic Controls in Single-Arm Trials
by: Bertolini, Daniele, et al.
Published: (2026)

Fragility Index for Time-to-Event Endpoints in Single-Arm Clinical Trials
by: Maity, Arnab Kumar, et al.
Published: (2024)

Semiparametric Piecewise Accelerated Failure Time Model for the Analysis of Immune-Oncology Clinical Trials
by: Sunami, Hisato, et al.
Published: (2024)

Designing Efficient Hybrid and Single-Arm Trials: External Control Borrowing and Sample Size Calculation
by: Gao, Yujing, et al.
Published: (2025)

Log-linear Model for Dual System Estimation and Computational Considerations
by: Lu, Zhiyuan
Published: (2026)

The Backfill i3+3 Design for Dose-Finding Trials in Oncology
by: Liu, Jiaxin, et al.
Published: (2023)

WATCH: A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors
by: Sechidis, Konstantinos, et al.
Published: (2024)

BOIN Designs for Dose Escalation With Selected Dose Combinations in Oncology Phase I Trials
by: Chen, Yuxuan, et al.
Published: (2026)

Pharmacometrics-Enabled DOse OPtimization (PEDOOP) for Seamless Phase I-II Trials in Oncology
by: Yuan, Shijie, et al.
Published: (2023)

Learning from Literature: Integrating LLMs and Bayesian Hierarchical Modeling for Oncology Trial Design
by: Gong, Guannan, et al.
Published: (2026)

Behavioral Carry-Over Effect and Power Consideration in Crossover Trials
by: Shi, Danni, et al.
Published: (2023)

Considerations for the Integration of Randomized Controlled Trials and Real-World Data
by: Qiu, Sky, et al.
Published: (2026)

Evaluation of Minimal Residual Disease as a Surrogate for Progression-Free Survival in Hematology Oncology Trials: A Meta-Analytic Review
by: She, Jane, et al.
Published: (2026)

Decentralized Clinical Trials in the Era of Real-World Evidence: A Statistical Perspective
by: Chen, Jie, et al.
Published: (2024)

The Modified Combo i3+3 Design for Novel-Novel Combination Dose-Finding Trials in Oncology
by: Liu, Jiaxin, et al.
Published: (2024)

A Seamless Phase II/III Design with Dose Optimization for Oncology Drug Development
by: Li, Yuhan, et al.
Published: (2024)

Precision Dose-Finding Design for Phase I Oncology Trials by Integrating Pharmacology Data
by: Lee, Kyong Ju, et al.
Published: (2025)

Risk-Calibrated Process Capability Approval with Finite Samples
by: Jiang, Fei, et al.
Published: (2026)

Principled Frequentist Estimation of Racial Disparity in Credit Approval under Unobserved Race
by: Fisher, Sam, et al.
Published: (2025)

Defining Utility as a Measure of Preference Under Uncertainty in Phase I-II Oncology Dose Finding Trials
by: Hall, Andrew, et al.
Published: (2025)

Challenges and Possible Strategies to Address Them in Rare Disease Drug Development: A Statistical Perspective
by: Chen, Jie, et al.
Published: (2024)

On the Calibration of Bayesian Success Criteria and Operating Characteristics for Clinical Trials
by: Yang, Peng, et al.
Published: (2026)

Use of Real-World Data and Real-World Evidence in Rare Disease Drug Development: A Statistical Perspective
by: Chen, Jie, et al.
Published: (2024)

Finite-Sample Decision Instability in Threshold-Based Process Capability Approval
by: Jiang, Fei, et al.
Published: (2026)

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties
by: Cui, Ying, et al.
Published: (2025)

Regulatory Expectations for Bayesian Methods in Drug and Biologic Clinical Trials: A Practical Perspective on FDA's 2026 Draft Guidance
by: Ji, Yuan, et al.
Published: (2026)

Bayesian Deployment Approval for Learned Landing Controllers under Finite Rollout Validation
by: Jiang, Fei, et al.
Published: (2026)

Personalized Oncology: Feasibility of Evaluating Treatment Effects for Individual Patients
by: Jang, Lydia, et al.
Published: (2025)

On Assessing Overall Survival (OS) in Oncology Studies
by: Hsu, Jason C.
Published: (2025)

Evaluating causal effects on time-to-event outcomes in an RCT in Oncology with treatment discontinuation
by: Ballerini, Veronica, et al.
Published: (2023)

Geoinformation dependencies in geographic space and beyond
by: Wang, Jon, et al.
Published: (2025)

Covariate Ordered Systematic Sampling as an Improvement to Randomized Controlled Trials
by: Jobson, Deddy, et al.
Published: (2024)

Programming Geotechnical Reliability Algorithms using Generative AI
by: Sharma, Atma, et al.
Published: (2025)

Analyzing Population-Level Trials as N-of-1 Trials: an Application to Gait
by: Zhou, Lin, et al.
Published: (2022)

A Practical Analysis Procedure on Generalizing Comparative Effectiveness in the Randomized Clinical Trial to the Real-world Trialeligible Population
by: Jiang, Kuan, et al.
Published: (2024)

Use of Mobile Application for Improving Drug Compliance and Clinical Outcomes: A Randomized Controlled Trial
by: Pramod Kumar Mehta, et al.
Published: (2026)

Generalized Design of Basket Trials with P-value Combination Test
by: Zhou, Heng, et al.
Published: (2024)

Regulatory Considerations for Using Artificial Intelligence Models to Reduce Sample Sizes in Registrational Studies
by: Smith, Aaron M., et al.
Published: (2026)

Bayesian Inference General Procedures for A Single-subject Test Study
by: Li, Jie, et al.
Published: (2024)

Nonparametric Bayesian Multi-Treatment Mixture Cure Survival Model with Application in Pediatric Oncology
by: Chang, Peter, et al.
Published: (2025)